Tag Archive for: complement

Commit Biologics announces €5.5m seed financing extension investment by Korys to further develop its Bispecific Complement Engaging (BiCE™) platform

/in

Additional funding from new investor Korys, joining existing syndicate members Novo Holdings and Bioqube Ventures, brings total seed financing to €21.5m Funds will be used to further develop Commit’s BiCE platform and move towards drug candidate (DC) selection Eva Van Overmeire, Senior Investment Manager at Korys, also joins Commit’s Board of Directors Mikkel Wandahl Pedersen […]

Read more

Commit Biologics appoints accomplished R&D executive, Dr Janine Schuurman, to its Board of Directors

/in

Former senior vice president of antibody research at Genmab who has co-invented numerous FDA-approved therapeutic antibodies and as well as its DuoBody® bi-specific antibody platform. Brings decades of experience in developing strong pipelines of antibody-based drugs from platforms, growing scientific teams and managing partnerships with Pharma companies Appointment comes as Commit looks to progress towards […]

Read more

Commit Biologics appoints Mikkel Wandahl Pedersen as Chief Scientific Officer

/in

Highly experienced leader with demonstrated track record of antibody-based drug discovery and pipeline advancement Strengthens Commit’s leadership team after emerging from stealth with €16m seed financing Dr Pedersen will spearhead research and development of Commit’s BiCETM technology as the Company moves towards drug candidate (DC) nomination Aarhus, Denmark, 15 October 2024 – Commit Biologics (“Commit”), […]

Read more

Commit Biologics to present data on its Bispecific Complement Engaging (BiCE™) platform at the 16th International Conference on Complement Therapeutics

/in

Commit Biologics is pioneering a novel approach to activating the complement component of the immune system to treat cancer and autoimmune diseases Poster to be presented on Commit’s Bispecific Complement Engaging (BiCE™) platform   Aarhus, Denmark, 10 June 2024 – Commit Biologics (“Commit”), a pioneer in the activation of the complement system to treat cancer […]

Read more

Commit Biologics launches with €16m seed financing to pioneer complement system activation to treat cancer and autoimmune disease

/in

Financing led by Bioqube Ventures and Novo Holdings Commit is pioneering a novel approach to activating the complement component of the immune system to treat cancer and autoimmune diseases Its unique bispecific technology (BiCE™) engages the complement system, unleashing its power to selectively kill target cells Spin-out from Aarhus University in Denmark, a world leader […]

Read more